Get started
Author

Nicolai Mader

Observed names: Mader, Nicolai, N Mader, N. Mader
ORCID: 0000-0002-1636-9959
Observed ORCID: 0000-0002-1636-9959
OpenAlex ID: A5032711879
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
2021 · Daniel Groener, Cam Tu Nguyen, et al. · EJNMMI Research · 72
PDF
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
2023 · Nicolai Mader, Christina Nguyen Ngoc, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 41
PDF
Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
2023 · Daniel Groener, Sina Schneider, et al. · Cancers · 26
PDF
Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride
2022 · Justus Baumgarten, Daniel Groener, et al. · Cancers · 24
PDF
Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
2021 · Daniel Groener, Justus Baumgarten, et al. · Cancers · 18
PDF
Real-World Comparison of Cabazitaxel Versus177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
2024 · Mike Wenzel, Florestan Koll, et al. · Journal of Nuclear Medicine · 16
PDF
Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT
2023 · Daniel Groener, Jennifer Wichert, et al. · Cancers · 13
PDF
Heat sink effects in thyroid bipolar radiofrequency ablation: an ex vivo study
2023 · Konrad Klimek, Nicolai Mader, et al. · Scientific Reports · 9
PDF
Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
2023 · Nicolai Mader, Christina Schoeler, et al. · Cancers · 9
PDF
Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
2021 · Nicolai Mader, Daniel Groener, et al. · Cancers · 9
PDF
Thyroid papillary cancer elements arising from struma ovarii with benign peritoneal strumosis: Utility of iodine‐123 imaging in diagnostics and treatment planning
2023 · Daniel Groener, Justus Baumgarten, et al. · Clinical Case Reports · 5
PDF
Renal Function after Radioligand Treatment with 177Lu-PSMA-617
2020 · Christina Nguyen Ngoc, Christian Happel, et al. · Journal of Nuclear Medicine · 4
Safety and Efficacy of Selective Internal Radionuclide Therapy with 90Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization
2024 · Alexander Bellendorf, Nicolai Mader, et al. · Pharmaceuticals · 3
PDF
Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
2021 · Amir Sabet, Nicolai Mader, et al. · Pharmaceuticals · 3
PDF
Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer
2020 · Nicolai Mader, Justus Baumgarten, et al. · Journal of Nuclear Medicine · 1
Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.
2025 · Mike Wenzel, Florestan Koll, et al. · Journal of Clinical Oncology
PDF
Radioiodine Therapy in Patients with Graves’ Disease and Concomitant Functioning Nodules (Marine-Lenhart Syndrome)
2023 · J. Baumgarten, C. Happel, et al. · Nuklearmedizin - NuclearMedicine
Ultrasound-guided Polidocanol Instillation in Symptomatic Cystic Thyroid Nodules – Adopting a Re-aspiration Protocol
2023 · D. Groener, J. Baumgarten, et al. · Nuklearmedizin - NuclearMedicine
Clinical Evaluation of Salivary Gland-Function after 177Lu-PSMA Radioligand Therapy
2023 · N. Mader, T. Weight, et al. · Nuklearmedizin - NuclearMedicine
Lutetium-177-Radioligandentherapie beim Prostatakarzinom
2022 · Frank Grünwald, Nicolai Mader, et al. · Uro-News
Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
2021 · Justus Baumgarten, Daniel Groener, et al. · Journal of Nuclear Medicine
Konzentrationsbasiertes Programm zur SIRT-Dosimetrie
2021 · WT Kranert, C Happel, et al. · Nuklearmedizin - NuclearMedicine
Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
2020 · Daniel Gröner, Justus Baumgarten, et al. · Journal of Nuclear Medicine
Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
2020 · Nicolai Mader, Christina Nguyen Ngoc, et al. · Journal of Nuclear Medicine
Works count: 28
Citation count: 253
H-index: 9
I10-index: 7
Year
Topic
Type